{"id":"https://openalex.org/W2952039293","doi":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","title":"PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY","display_name":"PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY","publication_year":2019,"publication_date":"2019-06-01","ids":{"openalex":"https://openalex.org/W2952039293","doi":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","mag":"2952039293"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000560524.63281.bc","doi":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058384217","display_name":"Rocio Montes De Oca","orcid":"https://orcid.org/0000-0002-6576-7240","observed_orcids":["https://orcid.org/0000-0002-6576-7240"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Montes De Oca","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"S. Bhattacharya","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Bhattacharya","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009598034","display_name":"Nick Vitali","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. Vitali","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"K. Patel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Patel","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074622859","display_name":"Heather Kaczynski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Kaczynski","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069580658","display_name":"Hong Shi","orcid":"https://orcid.org/0009-0006-0886-1501","observed_orcids":["https://orcid.org/0009-0006-0886-1501","https://orcid.org/0000-0003-0495-447X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H.Z. Shi","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039345673","display_name":"Christina Blackwell","orcid":"https://orcid.org/0009-0000-5585-3658","observed_orcids":["https://orcid.org/0009-0000-5585-3658"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Blackwell","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000219610","display_name":"Laura Seestaller\u2010Wehr","orcid":"https://orcid.org/0009-0004-4149-5203","observed_orcids":["https://orcid.org/0009-0004-4149-5203"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Seestaller-Wehr","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"D. Cooper","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Cooper","raw_affiliation_strings":["Statistics, Target Sciences, GSK, Collegeville, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Statistics, Target Sciences, GSK, Collegeville, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074442761","display_name":"Hollie J. Jackson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. Jackson","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044999604","display_name":"Lyuben M. Tsvetkov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Tsvetkov","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056768522","display_name":"Oliver Kepp","orcid":"https://orcid.org/0000-0002-6081-9558","observed_orcids":["https://orcid.org/0000-0002-6081-9558"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"O. Kepp","raw_affiliation_strings":["Institut Gustave Roussy, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090847503","display_name":"Mark Creighton-Gutteridge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"M. Creighton-Gutteridge","raw_affiliation_strings":["Oncology Cell Therapy RU, GSK, Stevenage, Hertfordshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Cell Therapy RU, GSK, Stevenage, Hertfordshire, United Kingdom","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015114773","display_name":"Christopher B. Hopson","orcid":"https://orcid.org/0009-0004-5823-3891","observed_orcids":["https://orcid.org/0009-0004-5823-3891"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Hopson","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Yang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Yang","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075296559","display_name":"Guido Kroemer","orcid":"https://orcid.org/0000-0002-9334-4405","observed_orcids":["https://orcid.org/0000-0002-9334-4405"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"G. Kroemer","raw_affiliation_strings":["Institut Gustave Roussy, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Gustave Roussy, Paris, France","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046901107","display_name":"Patrick A. Mayes","orcid":"https://orcid.org/0000-0001-9104-4161","observed_orcids":["https://orcid.org/0000-0001-9104-4161"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Mayes","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113872669","display_name":"Christopher A. Shelton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Shelton","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110160811","display_name":"A Alavi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Alavi","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086481435","display_name":"Axel Hoos","orcid":"https://orcid.org/0000-0001-5269-9376","observed_orcids":["https://orcid.org/0000-0001-5269-9376"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Hoos","raw_affiliation_strings":["Oncology R&D"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":null,"has_fulltext":false,"cited_by_count":19,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"S1","first_page":"231","last_page":"231"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9916999936103821,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.00570000009611249,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8650000095367432},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.9089999794960022},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9559999704360962},{"id":"https://openalex.org/keywords/immunogenic-cell-death","display_name":"immunogenic cell death","score":0.9800000190734863},{"id":"https://openalex.org/keywords/ox40-agonist","display_name":"OX40 agonist","score":0.7940000295639038},{"id":"https://openalex.org/keywords/monomethyl-auristatin-f","display_name":"monomethyl auristatin F","score":0.7170000076293945},{"id":"https://openalex.org/keywords/dolastatin","display_name":"dolastatin","score":0.628000020980835},{"id":"https://openalex.org/keywords/calreticulin","display_name":"calreticulin","score":0.8529999852180481},{"id":"https://openalex.org/keywords/hmgb1","display_name":"HMGB1","score":0.9700000286102295},{"id":"https://openalex.org/keywords/er-stress-response","display_name":"ER stress response","score":0.5789999961853027},{"id":"https://openalex.org/keywords/adaptive-immune-response","display_name":"adaptive immune response","score":0.5139999985694885},{"id":"https://openalex.org/keywords/tumor-infiltrating-lymphocytes","display_name":"tumor-infiltrating lymphocytes","score":0.5709999799728394},{"id":"https://openalex.org/keywords/t-cell-proliferation","display_name":"T cell proliferation","score":0.37599998712539673}],"concepts":[{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.6223165392875671},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6072279214859009},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5248280167579651},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4724588394165039},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.45744583010673523},{"id":"https://openalex.org/C2777877232","wikidata":"https://www.wikidata.org/wiki/Q17144704","display_name":"Immunogenic cell death","level":4,"score":0.4573793113231659},{"id":"https://openalex.org/C2777325958","wikidata":"https://www.wikidata.org/wiki/Q1069596","display_name":"Antibody-drug conjugate","level":4,"score":0.4443681538105011},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4421742260456085},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.42805153131484985},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.42614713311195374},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.411193311214447},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.345206618309021},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.3229866623878479},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.1643877625465393},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1097/01.hs9.0000560524.63281.bc","doi":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000560524.63281.bc","doi":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000560524.63281.bc","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3177941998","https://openalex.org/W1982877913","https://openalex.org/W2796115040","https://openalex.org/W2530060405","https://openalex.org/W2047148621","https://openalex.org/W2476275359","https://openalex.org/W2615766380","https://openalex.org/W4246168528","https://openalex.org/W2901760736","https://openalex.org/W3031511771"],"abstract_inverted_index":{"Background:":[0],"Multiple":[1],"myeloma":[2,40,61],"(MM)":[3],"is":[4,43,64,78,85,323,337,358,371],"the":[5,50,89,135,155,159,238,245,252,262,266,304,345,354],"second":[6],"most":[7],"common":[8],"hematological":[9],"malignancy":[10],"and":[11,37,144,177,187,217,227,233,276,296,310,328,332,336,394,398,403,408,419,431,449],"remains":[12],"an":[13,65,301],"incurable":[14],"disease.":[15],"Therefore,":[16],"novel":[17,443],"targeted":[18],"therapies":[19],"are":[20,96,288],"in":[21,29,59,178,215,218,255,281,315,429,432],"need.":[22],"Achieving":[23],"a":[24,30,44,71,86,107,152,188,372,388,442],"60%":[25],"overall":[26],"response":[27,231],"rate":[28],"phase":[31],"1":[32],"clinical":[33,453],"trial":[34],"for":[35,447,452],"relapsed":[36],"refractory":[38],"multiple":[39,60],"patients,":[41],"GSK2857916":[42,63,119,171,202,210,253,271,322,348,386,448],"promising":[45],"drug":[46,141],"candidate":[47],"that":[48,77,112,209,270,375],"targets":[49],"B-cell":[51],"Maturation":[52],"Antigen":[53],"(BCMA)":[54],"protein,":[55],"expressed":[56],"almost":[57],"exclusively":[58],"cells.":[62,381],"antibody-drug":[66],"conjugate":[67,142],"(ADC)":[68],"consisting":[69],"of":[70,88,92,109,132,138,154,158,164,213,225,235,247,251,303,341,347,367,385,400,410,445],"humanized":[72],"anti":[73],"BCMA":[74,197],"monoclonal":[75],"antibody":[76,264,393],"conjugated":[79],"to":[80,102,122,168,194,200,265,291,349,360,413],"monomethyl":[81],"auristatin-F":[82],"(MMAF).":[83],"MMAF":[84],"member":[87],"dolastatin":[90],"family":[91],"microtubule":[93],"inhibitors,":[94],"which":[95],"potent":[97],"antitumor":[98],"agents":[99],"also":[100],"linked":[101],"immunogenic":[103,436],"cell":[104,110,222,330,437],"death":[105,111,438],"(ICD),":[106],"type":[108],"can":[113,376],"stimulate":[114,377],"host":[115,305],"immune":[116,258,289,306,355],"responses.":[117],"Pre-clinically,":[118],"was":[120,167],"shown":[121],"mediate":[123,350],"anti-tumor":[124,204,319,351,417],"activity":[125,320,352,418],"through":[126,353],"several":[127],"mechanisms":[128],"including":[129],"(a)":[130],"induction":[131],"apoptosis,":[133],"following":[134],"intracellular":[136],"release":[137],"active":[139],"cytotoxic":[140],"Cys-mcMMAF,":[143],"(b)":[145],"enhanced":[146],"antibody-dependent":[147],"cellular":[148],"cytotoxicity":[149],"(ADCC)":[150],"as":[151,174,221,249,441],"result":[153],"\u2018engineered\u2019":[156],"afucosylation":[157],"antibody.":[160],"Aims:":[161],"The":[162],"goal":[163],"these":[165,368],"studies":[166],"explore":[169],"potential":[170,346],"immune-modulatory":[172,364,457],"activities":[173],"single":[175,425],"agent":[176],"combination":[179],"with":[180,293,363,387,455],"immune-modulators.":[181],"Methods:":[182],"We":[183,207,268,382],"developed":[184],"cell-based":[185],"assays":[186],"subcutaneous":[189],"syngeneic":[190],"tumor":[191,241,274,298,311],"model":[192],"engineered":[193],"express":[195],"human":[196],"(EL4-hBCMA":[198],"lymphoma)":[199],"assess":[201],"immune-mediated":[203],"activity.":[205],"Results:":[206],"report":[208],"induces":[211,277],"hallmarks":[212,409],"ICD":[214,334],"vivo":[216,433],"vitro,":[219],"such":[220],"surface":[223],"expression":[224],"calreticulin":[226],"other":[228],"ER":[229],"stress":[230],"proteins,":[232],"secretion":[234],"HMGB1.":[236],"In":[237],"immune-competent":[239],"EL4-hBCMA":[240,284,297],"model,":[242,317],"we":[243],"examined":[244],"contribution":[246],"MMAF,":[248],"part":[250],"molecule,":[254],"driving":[256],"adaptive":[257],"responses":[259,280,423],"by":[260,321,325],"comparing":[261],"non-conjugated":[263],"ADC.":[267],"show":[269],"treatment":[272],"inhibits":[273],"growth":[275],"durable":[278,318,421],"complete":[279,422],"mice":[282],"carrying":[283],"tumors.":[285],"Responding":[286],"animals":[287],"resistant":[290],"re-challenge":[292],"parental":[294],"EL4":[295],"cells,":[299],"suggesting":[300],"engagement":[302],"system,":[307,356],"immunologic":[308],"memory":[309],"antigen":[312,405],"spreading.":[313],"Indeed,":[314],"this":[316],"characterized":[324],"T,":[326],"NK":[327],"dendritic":[329,402],"infiltration":[331,397],"increased":[333,396,420],"markers,":[335],"abrogated":[338],"upon":[339],"depletion":[340],"CD8+":[342],"T-cells.":[343],"Given":[344],"there":[357],"rationale":[359,451],"evaluate":[361],"combinations":[362,384,454],"therapies.":[365,458],"One":[366],"immune-modulators,":[369],"OX40,":[370],"co-stimulatory":[373],"molecule":[374],"T-cells":[378,407],"against":[379],"cancer":[380],"evaluated":[383],"murine":[389],"anti-OX40":[390],"(OX86)":[391],"agonist":[392],"demonstrated":[395],"activation":[399],"intratumoral":[401],"T-cells,":[404],"presenting":[406],"ICD,":[411],"leading":[412],"statistically":[414],"significant":[415],"superior":[416],"over":[424],"agents.":[426],"Summary/Conclusion:":[427],"Our":[428],"vitro":[430],"results":[434],"support":[435],"and/or":[439],"immune-modulation":[440],"mechanism":[444],"action":[446],"provide":[450],"various":[456]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2019-06-27T00:00:00"}